All Updates

All Updates

icon
Filter
Funding
Waypoint Bio raises USD 14.5 million in seed funding to develop CAR T-cell therapies for oncology
Cell & Gene Therapy
Jun 28, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Jun 28, 2024

Waypoint Bio raises USD 14.5 million in seed funding to develop CAR T-cell therapies for oncology

Funding

  • Novel cell therapy developer Waypoint Bio has secured USD 14.5 million in a seed funding round led by Hummingbird Ventures, with participation from Recode Ventures and Fifty Years.

  • The firm plans to allocate funds to develop CAR T-cell therapies that exhibit efficacy against tumor microenvironments, using in vivo spatial pooled screening technology. Successively, the company will focus on developing Treg therapies targeting autoimmune diseases.

  • Waypoint Bio is a biotechnology company that develops cell therapies for solid tumors. The company's proprietary platform integrates high-resolution spatial biology with pooled screening techniques, allowing rapid and accurate in vivo testing. This approach enables the evaluation of cell therapies in three-dimensional tissue environments, addressing the complexities of solid tumor microenvironments.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.